Ignite Creation Date:
2025-12-24 @ 5:12 PM
Ignite Modification Date:
2025-12-28 @ 12:34 AM
Study NCT ID:
NCT00441350
Status:
COMPLETED
Last Update Posted:
2021-07-28
First Post:
2007-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension
Sponsor:
Menarini Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-07
Start Date Type:
None
Primary Completion Date:
2008-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-05
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-27
First Submit QC Date:
None
Study First Post Date:
2007-02-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-05-06
Results First Submit QC Date:
None
Results First Post Date:
2021-07-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-08
Last Update Post Date:
2021-07-28
Last Update Post Date Type:
ACTUAL